Less than a week after making a regulatory submission for a $1 million capital raise, prostate health company ProUroCare Medical, based in Eden Prairie, Minnesota, announced that it has secured market ...

Lucida’s software is designed to identify prostate cancer ‘within minutes’ and overcome diagnosis delays associated with ...

The MarketWatch News Department was not involved in the creation of this content. Oxford, UK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Topical summits in Dubai, Berlin, Nanjing, Basel, Lisbon, London and ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...

Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...

The collaboration includes the initial validation and deployment of Ibex Prostate within HNL Lab Medicine’s LDT workflow.

Charlotte, N.C.-based SonaCare Medical earned clearance from the Food and Drug Administration for a new version of its Sonablate device. Sonablate, intended for use in the focused ablation of prostate ...

Oxford, UK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Topical summits in Dubai, Berlin, Nanjing, Basel, Lisbon, London and other cities discussed the uniqueness of Dr Allen's Devices, a new revolutionary ...